Cancer Data Trends 2024: Lung Cancer

Article Type

Changed

Fri, 03/22/2024 - 10:44

Display Headline

Click to view more from Cancer Data Trends 2024.

References

1. Wolf AMD, Oeffinger KC, Shih TYC, et al. Screening for lung cancer: 2023 guideline update from the American Cancer Society. CA Cancer J Clin. 2023;10.3322/caac.21811. doi:10.3322/caac.21811

2. US Department of Veterans Affairs. VA promotes high-quality, patient-centered lung cancer screening for veterans. Published June 15, 2023. Accessed December 18, 2023. http://www.hsrd.research.va.gov/impacts/lcs.cfm

3. Navuluri N, Morrison S, Green CL, et al. Racial disparities in lung cancer screening among veterans, 2013 to 2021. JAMA Netw Open. 2023;6(6):e2318795. doi:10.1001/jamanetworkopen.2023.18795

4. Bruno DS, Hess LM, Li X, Su EW, Patel M. Disparities in biomarker testing and clinical trial enrollment among patients with lung, breast, or colorectal cancers in the United States. JCO Precis Oncol. 2022;6:e2100427. doi:10.1200/PO.21.00427

5. Jalal SI, Guo A, Ahmed S, Kelley MJ. Analysis of actionable genetic alterations in lung carcinoma from the VA National Precision Oncology Program. Semin Oncol. 2022;S0093-7754(22)00054-9. doi:10.1053/j.seminoncol.2022.06.014

6. Williams CD, Allo MA, Gu L, Vashistha V, Press A, Kelley M. Health outcomes and healthcare resource utilization among veterans with stage IV non-small cell lung cancer treated with second-line chemotherapy versus immunotherapy. PLoS One. 2023;18(2):e0282020. doi:10.1371/journal.pone.0282020

7. US Food and Drug Administration. Oncology (cancer)/hematologic malignancies approval notifications. Updated December 15, 2023. Accessed December 18, 2023. https://www.fda.gov/drugs/resources-information-approved-drugs/oncology-cancer-hematologic-malignancies-approval-notifications

8. Paz-Ares L, Chen Y, Reinmuth N, et al. Durvalumab, with or without tremelimumab, plus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer: 3-year overall survival update from CASPIAN. ESMO Open. 2022;7(2):100408. doi:10.1016/j.esmoop.2022.100408

Author and Disclosure Information

Reviewed by Apar Kishor Ganti, MD, MS
Professor, Department of Medicine
University of Nebraska Medical Center
Staff Physician, Department of Internal Medicine
VA Nebraska-Western Iowa Health Care System
Omaha, NE

Apar Kishor Ganti, MD, MS, has disclosed the following relevant financial relationships:
Serve(d) as a director, officer, partner, employee, advisor, consultant, or trustee for: AstraZeneca; Flagship Biosciences; G1 Therapeutics; Jazz Pharmaceuticals; Cardinal Health; Mirati Therapeutics; Regeneron Pharmaceuticals; Sanofi; Genzyme; Eisai

Publications

Topics

Author and Disclosure Information

Reviewed by Apar Kishor Ganti, MD, MS
Professor, Department of Medicine
University of Nebraska Medical Center
Staff Physician, Department of Internal Medicine
VA Nebraska-Western Iowa Health Care System
Omaha, NE

Apar Kishor Ganti, MD, MS, has disclosed the following relevant financial relationships:
Serve(d) as a director, officer, partner, employee, advisor, consultant, or trustee for: AstraZeneca; Flagship Biosciences; G1 Therapeutics; Jazz Pharmaceuticals; Cardinal Health; Mirati Therapeutics; Regeneron Pharmaceuticals; Sanofi; Genzyme; Eisai

Author and Disclosure Information

Reviewed by Apar Kishor Ganti, MD, MS
Professor, Department of Medicine
University of Nebraska Medical Center
Staff Physician, Department of Internal Medicine
VA Nebraska-Western Iowa Health Care System
Omaha, NE

Apar Kishor Ganti, MD, MS, has disclosed the following relevant financial relationships:
Serve(d) as a director, officer, partner, employee, advisor, consultant, or trustee for: AstraZeneca; Flagship Biosciences; G1 Therapeutics; Jazz Pharmaceuticals; Cardinal Health; Mirati Therapeutics; Regeneron Pharmaceuticals; Sanofi; Genzyme; Eisai

Click to view more from Cancer Data Trends 2024.

References

1. Wolf AMD, Oeffinger KC, Shih TYC, et al. Screening for lung cancer: 2023 guideline update from the American Cancer Society. CA Cancer J Clin. 2023;10.3322/caac.21811. doi:10.3322/caac.21811

2. US Department of Veterans Affairs. VA promotes high-quality, patient-centered lung cancer screening for veterans. Published June 15, 2023. Accessed December 18, 2023. http://www.hsrd.research.va.gov/impacts/lcs.cfm

3. Navuluri N, Morrison S, Green CL, et al. Racial disparities in lung cancer screening among veterans, 2013 to 2021. JAMA Netw Open. 2023;6(6):e2318795. doi:10.1001/jamanetworkopen.2023.18795

4. Bruno DS, Hess LM, Li X, Su EW, Patel M. Disparities in biomarker testing and clinical trial enrollment among patients with lung, breast, or colorectal cancers in the United States. JCO Precis Oncol. 2022;6:e2100427. doi:10.1200/PO.21.00427

5. Jalal SI, Guo A, Ahmed S, Kelley MJ. Analysis of actionable genetic alterations in lung carcinoma from the VA National Precision Oncology Program. Semin Oncol. 2022;S0093-7754(22)00054-9. doi:10.1053/j.seminoncol.2022.06.014

6. Williams CD, Allo MA, Gu L, Vashistha V, Press A, Kelley M. Health outcomes and healthcare resource utilization among veterans with stage IV non-small cell lung cancer treated with second-line chemotherapy versus immunotherapy. PLoS One. 2023;18(2):e0282020. doi:10.1371/journal.pone.0282020

7. US Food and Drug Administration. Oncology (cancer)/hematologic malignancies approval notifications. Updated December 15, 2023. Accessed December 18, 2023. https://www.fda.gov/drugs/resources-information-approved-drugs/oncology-cancer-hematologic-malignancies-approval-notifications

8. Paz-Ares L, Chen Y, Reinmuth N, et al. Durvalumab, with or without tremelimumab, plus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer: 3-year overall survival update from CASPIAN. ESMO Open. 2022;7(2):100408. doi:10.1016/j.esmoop.2022.100408

References

1. Wolf AMD, Oeffinger KC, Shih TYC, et al. Screening for lung cancer: 2023 guideline update from the American Cancer Society. CA Cancer J Clin. 2023;10.3322/caac.21811. doi:10.3322/caac.21811

2. US Department of Veterans Affairs. VA promotes high-quality, patient-centered lung cancer screening for veterans. Published June 15, 2023. Accessed December 18, 2023. http://www.hsrd.research.va.gov/impacts/lcs.cfm

3. Navuluri N, Morrison S, Green CL, et al. Racial disparities in lung cancer screening among veterans, 2013 to 2021. JAMA Netw Open. 2023;6(6):e2318795. doi:10.1001/jamanetworkopen.2023.18795

4. Bruno DS, Hess LM, Li X, Su EW, Patel M. Disparities in biomarker testing and clinical trial enrollment among patients with lung, breast, or colorectal cancers in the United States. JCO Precis Oncol. 2022;6:e2100427. doi:10.1200/PO.21.00427

5. Jalal SI, Guo A, Ahmed S, Kelley MJ. Analysis of actionable genetic alterations in lung carcinoma from the VA National Precision Oncology Program. Semin Oncol. 2022;S0093-7754(22)00054-9. doi:10.1053/j.seminoncol.2022.06.014

6. Williams CD, Allo MA, Gu L, Vashistha V, Press A, Kelley M. Health outcomes and healthcare resource utilization among veterans with stage IV non-small cell lung cancer treated with second-line chemotherapy versus immunotherapy. PLoS One. 2023;18(2):e0282020. doi:10.1371/journal.pone.0282020

7. US Food and Drug Administration. Oncology (cancer)/hematologic malignancies approval notifications. Updated December 15, 2023. Accessed December 18, 2023. https://www.fda.gov/drugs/resources-information-approved-drugs/oncology-cancer-hematologic-malignancies-approval-notifications

8. Paz-Ares L, Chen Y, Reinmuth N, et al. Durvalumab, with or without tremelimumab, plus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer: 3-year overall survival update from CASPIAN. ESMO Open. 2022;7(2):100408. doi:10.1016/j.esmoop.2022.100408

Publications

Publications

Topics

Article Type

Display Headline

Cancer Data Trends 2024: Lung Cancer

Display Headline

Cancer Data Trends 2024: Lung Cancer

Disallow All Ads

Content Gating

No Gating (article Unlocked/Free)

Alternative CME

Disqus Comments

Default

Eyebrow Default

SLIDESHOW

Un-Gate On Date

Thu, 03/07/2024 - 12:15

Consolidated Pubs: Do Not Show Source Publication Logo

Use ProPublica

CFC Schedule Remove Status

Thu, 03/07/2024 - 17:30

Conference Recap Checkbox

Not Conference Recap

Clinical Edge

Display the Slideshow in this Article

Slide

Gating Strategy

No Gating

Medscape Article

Display survey writer

Reuters content

Disable Inline Native ads

WebMD Article

Slide Media

Caption

The VA adheres to USPSTF screening guidelines for lung cancer. At least 1 million veterans are eligible for screening, yet many fewer veterans are being screened.ACS, American Cancer Society; CT, computed tomography; USPSTF, US Preventive Services Task Force

Disable zoom

Off

Media Folder

Media Root

Caption

Black veterans are less likely than White veterans to complete screening for lung cancer.

Disable zoom

Off

Media Folder

Media Root

Disable zoom

Off

Media Folder

Media Root

Caption

Black patients with non-small cell lung cancer (NSCLC) in the general population also have lower rates of next-generation sequencing (NGS) testing, which is critical in providing patients with new targeted therapies. These discrepancies must be addressed to improve screening and treatment in lung cancer for minority groups.

Disable zoom

Off

Media Folder

Media Root

Caption

Age at consultation was evaluated by the following categories: <60, 60-65, 65-70, 70-75, >75

Disable zoom

Off

Media Folder

Media Root

Disable zoom

Off

Media Folder

Media Root

Caption

The frequency of EGFR mutations, RET rearrangement, MET exon 14 mutation, and ERBB2 small variants were less common and MET amplification was more common in veterans with lung adenocarcinoma compared to the general population.Veterans and general population groups are not matched on all criteria; therefore, these differences in mutations should be interpreted with caution.

Disable zoom

Off

Media Folder

Media Root

Caption

Recent clinical trials show that immunotherapy slightly improves overall survival in advanced NSCLC, particularly in the second-line setting. However, veterans still receive immunotherapy at lower rates than chemotherapy.

Disable zoom

Off

Media Folder

Media Root

Disable zoom

Off

Media Folder

Media Root

Disable zoom

Off

Media Folder

Media Root

Caption

The lung cancer treatment landscape is rapidly changing, with progress being made in NSCLC and small cell lung cancer (SCLC), and many new treatments on the horizon that will change the standard of care.In the SCLC space, CASPIAN was a recent trial of interest, leading to the approval of durvalumab.

Disable zoom

Off

Media Folder

Media Root

User login